February 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
8 citations
,
October 2021 in “Microbiology spectrum” Researchers identified five new potential targets for leishmaniasis treatment, suggesting repurposing existing drugs could be effective.
July 2024 in “Journal of Investigative Dermatology” A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
8 citations
,
July 2019 in “Pure and Applied Chemistry” Some natural compounds from Iris plants can block enzymes related to certain disorders, with a few affecting both targeted enzymes.
2 citations
,
March 2025 in “Journal of Translational Autoimmunity” Targeting the AhR pathway may help treat alopecia areata.
April 2023 in “Journal of Investigative Dermatology” A new treatment for hair loss shows promise with fewer side effects.
50 citations
,
July 2021 in “Nature Communications” The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
April 2016 in “Journal of Investigative Dermatology” Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
3 citations
,
November 2024 in “Viruses” Cepharanthine may help treat Equid herpesvirus type 8 by reducing oxidative stress.
56 citations
,
November 2007 in “Molecular and cellular endocrinology” Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
January 2022 in “Drugs of Today”
April 2024 in “Expert opinion on emerging drugs” New treatments for male hair loss are being explored to improve effectiveness and reduce side effects.
3 citations
,
January 2023 in “Clinical cancer investigation journal” Some cannabinoid derivatives may be more effective than current drugs at targeting proteins relevant to prostate cancer treatment.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
September 2019 in “Journal of Investigative Dermatology” Targeted therapy with Ustekinumab significantly improved a skin condition called ILVEN, which is caused by mutations in the CARD14 gene.
December 2022 in “Small methods” A new hair loss treatment using dissolving microneedles was found to speed up hair growth and was more effective than daily use of common hair growth drugs.
2 citations
,
February 2018 in “International Research Journal of Pharmacy” Eclipta alba leaf alkaloids may help treat HIV by inhibiting the virus's activity.
January 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Semecarpus anacardium leaf extracts may offer safe, effective cancer treatment alternatives.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
40 citations
,
July 2023 in “Clinical Pharmacology & Therapeutics” Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
6 citations
,
November 2022 in “Journal of autoimmunity” JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
January 2005 in “Urologia Journal” 5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.